Основная статистика
| LEI | 549300060GVOSMWARH50 |
| CIK | 1756262 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TransMedics Group, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 30, 2025 |
TransMedics Reports Second Quarter 2025 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2025 Financial Results Andover, Mass. – July 30, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025. Recent Highlights ▪ Total revenue o |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 30, 2025 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 001-38891 83-2181531 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 200 Minuteman Road Andover, Massachusetts 01810 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 8, 2025 |
TransMedics Reports First Quarter 2025 Financial Results Exhibit 99.1 TransMedics Reports First Quarter 2025 Financial Results Andover, Mass. – May 8, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights ▪ Total revenue of |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 10, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 10, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 27, 2025 |
TransMedics Group, Inc. Insider Trading Policy Exhibit 19.1 transmedics group, inc. INSIDER TRADING Policy 1. Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of TransMedics Group, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors (the “Board”) has adop |
|
| February 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction TransMedics, Inc. Delaware TransMedics, B.V. The Netherlands TransMedics Pty Ltd. Australia TransMedics GmbH Germany Summit Aviation, Inc. Montana Northside Property Group, LLC Montana |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 27, 2025 |
Offer Letter dated as of November 26, 2024, by and between TransMedics, Inc. and Gerardo Hernandez Exhibit 10.42 November 26 2024 Dear Gerardo, On behalf of TransMedics, Inc., (the "Company"), I am very pleased to offer you employment with the Company contingent upon successful completion of the reference and background check processes, as well as verification of your eligibility for employment within three business days of the Start Date pursuant to the Immigration Reform and Control Act. This |
|
| February 27, 2025 |
Transition Agreement, by and between TransMedics, Inc. and Stephen Gordon, dated December 2, 2024 Exhibit 10.41 November 26, 2024 VIA EMAIL Stephen Gordon Dear Stephen: This letter agreement (this “Agreement”) confirms the terms of the remainder of your employment with TransMedics, Inc. (the “Company”) and your engagement as a consultant by the Company, as follows: 1. Transition Period. a. Transition. Subject to earlier termination as provided herein, from the date hereof through December 2, 2 |
|
| February 27, 2025 |
TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results Andover, Mass. – February 27, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Rece |
|
| February 27, 2025 |
Exhibit 10.43 TRANSMEDICS, INC. Executive Retention Agreement THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”) by and between TransMedics, Inc., a Delaware corporation (the “Company”), and Gerardo P. Hernandez Omana (the “Executive”) is made as of November 26, 2024 and effective as of the date the Executive begins employment with the Company (the “Effective Date”). WHEREAS, the Board of Direc |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Gr |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 2, 2024 |
Exhibit 99.1 TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook Andover, Mass. – December 2, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Her |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| October 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 28, 2024 |
TransMedics Reports Third Quarter 2024 Financial Results Exhibit 99.1 TransMedics Reports Third Quarter 2024 Financial Results Andover, Mass. – October 28, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights ▪ Total re |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| July 31, 2024 |
TransMedics Reports Second Quarter 2024 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2024 Financial Results Andover, Mass. – July 31, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights ▪ Total revenue o |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 001-38891 (State or other jurisdiction of incorporation) (Commission file number) 200 Minuteman Road Andover, Massachusetts 01810 (Address of principal executive office) (Zip Code) Stephen Gordon C |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| April 30, 2024 |
TransMedics Reports First Quarter 2024 Financial Results Exhibit 99.1 TransMedics Reports First Quarter 2024 Financial Results Andover, Mass. – April 30, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights ▪ Net revenue of |
|
| April 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2024 |
TransMedics Group Inc. Policy for Recoupment of Incentive Compensation Exhibit 97.1 TRANSMEDICS GROUP, INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of TransMedics Group, Inc. (the “Company”) has adopted this policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based |
|
| February 27, 2024 |
Exhibit 10.34 Execution Version ASSUMPTION AGREEMENT This ASSUMPTION AGREEMENT, dated as of December 22, 2023, is executed and delivered by Summit Aviation, Inc., a Montana corporation, and Northside Property Group, LLC, a Montana limited liability company (collectively, the “Additional Grantors”), in favor of CANADIAN IMPERIAL BANK OF COMMERCE, as administrative agent and collateral agent (in suc |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Gr |
|
| February 27, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Jurisdiction TransMedics, Inc. Delaware TransMedics, B.V. The Netherlands TransMedics Pty Ltd. Australia TransMedics GmbH Germany Summit Aviation, Inc. Montana Northside Property Group, LLC Montana |
|
| February 26, 2024 |
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results Andover, Mass. – February 26, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Rece |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 14, 2024 |
EX-99.A 2 d728380dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| February 14, 2024 |
EX-99.B 3 d728380dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| February 14, 2024 |
TMDX / TransMedics Group, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d728380dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Transmedics Group Inc (Name of Issuer) Common Shares (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 13, 2024 |
TMDX / TransMedics Group, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02099-transmedicsgroupinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: TransMedics Group Inc Title of Class of Securities: Common Stock CUSIP Number: 89377M109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to de |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 13, 2023 |
Exhibit 10.1 Execution Version THIRD AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO GUARANTEE AND COLLATERAL AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO GUARANTEE AND COLLATERAL AGREEMENT, dated as of November 9, 2023 (this “Amendment”), is made by and among TRANSMEDICS GROUP, INC., a Massachusetts corporation (the “Borrower”), the Guarantors party hereto, the L |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 6, 2023 |
TransMedics Reports Third Quarter 2023 Financial Results Exhibit 99.1 TransMedics Reports Third Quarter 2023 Financial Results Andover, Mass. – November 6, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023. Recent Highlights ▪ Net reve |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 12, 2023 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 16, 2023 |
TransMedics Completes Acquisition of Summit Aviation Exhibit 99.1 TransMedics Completes Acquisition of Summit Aviation Andover, Mass. – August 16, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. chart |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 4, 2023 |
Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TransMedics Group, Inc. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| August 4, 2023 |
Power of attorney (included in the signature page to this Registration Statement). S-8 As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 3, 2023 |
TransMedics Reports Second Quarter 2023 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2023 Financial Results Andover, Mass. – August 3, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023. Recent Highlights ▪ Net revenue of |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 29, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of June 23, 2023 (this “Second Amendment”), is made by and among TRANSMEDICS GROUP, INC., a Massachusetts corporation (the “Borrower”), the Lenders party hereto and CANADIAN IMPERIAL BANK OF COMMERCE as administrative agent for the Lenders (the “Administrative Agent”). Ca |
|
| May 26, 2023 |
EX-10.1 Exhibit 10.1 TRANSMEDICS GROUP, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN (as amended through May 25, 2023) 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those terms. 2. PURPOSE The Plan is intended to advance the interests of the Company by providing for the grant to Participants |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 11, 2023 |
EX-10.1 Exhibit 10.1 $400,000,000 TRANSMEDICS GROUP, INC. 1.50% Convertible Senior Notes due 2028 PURCHASE AGREEMENT May 8, 2023 May 8, 2023 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC as Representatives of the several Initial Purchasers listed in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York |
|
| May 11, 2023 |
EX-10.2 Exhibit 10.2 [Dealer] To: TransMedics Group, Inc. 200 Minuteman Road Andover, MA 01810 Attention: [[] Telephone No.: []] From: [] Re: [Base]1[Additional]2 Capped Call Transaction Ref. No: [] Date: [], 2023 Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 11, 2023 |
EX-4.1 Exhibit 4.1 TRANSMEDICS GROUP, INC., as Issuer, AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 11, 2023 1.50% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 . Definitions 1 Section 1.02 . References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01 . De |
|
| May 9, 2023 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of May 8, 2023 (this “First Amendment”), is made by and among TRANSMEDICS GROUP, INC., a Massachusetts corporation (the “Borrower”), the Lenders party hereto and CANADIAN IMPERIAL BANK OF COMMERCE as administrative agent for the Lenders (the “Administrative Agent”). Capitalized terms used bu |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 1, 2023 |
TransMedics Reports First Quarter 2023 Financial Results Exhibit 99.1 TransMedics Reports First Quarter 2023 Financial Results Andover, Mass. – May 1, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights ▪ Net revenue of $4 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Gr |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 24, 2023 |
EX-10.2 Exhibit 10.2 Name: [] Number of Restricted Stock Units: [] Date of Grant: [] Vesting Commencement Date: [] TRANSMEDICS GROUP, INC. INDUCEMENT PLAN INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT This agreement (this “Agreement”) evidences a grant (the “Award”) of Restricted Stock Units (“RSUs”) by the Company to the individual named above (the “Participant”), pursuant to and subject to the term |
|
| February 24, 2023 |
EX-10.1 Exhibit 10.1 Name: [] Number of Restricted Stock Units: [] Date of Grant: [] Vesting Commencement Date: [] TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT This agreement (this “Agreement”) evidences a grant (the “Award”) of Restricted Stock Units (“RSUs”) by the Company to the individual named above (the “Participant”), pursuant to and subject to the terms |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 22, 2023 |
TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results Andover, Mass. – February 22, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2022. Rece |
|
| February 14, 2023 |
TMDX / TransMedics Group Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d412661dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Transmedics Group Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89377M109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 9, 2023 |
TMDX / TransMedics Group Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv02065-transmedicsgroupinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: TransMedics Group Inc. Title of Class of Securities: Common Stock CUSIP Number: 89377M109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursua |
|
| February 2, 2023 |
TMDX / TransMedics Group Inc / CREDIT SUISSE AG/ - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* TransMedics Group, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 2, 2023 |
EX-99.1 2 ex991.htm EX-99.1 In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets |
|
| November 4, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS of TRANSMEDICS GROUP, INC. ARTICLE I Meetings of Shareholders Section 1. Place. Meetings of the shareholders shall be held at the principal office of the corporation or at such other place as may be determined by the board of directors or an officer designated by the board of directors and identified in the notice to shareholders of such meeting. Sect |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| November 3, 2022 |
Exhibit 99.1 TransMedics Reports Third Quarter 2022 Financial Results Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $80 million to $85 million Andover, Mass. ? November 3, 2022 - TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ trans |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 TransMedics Group, Inc. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2022 |
EX-1.1 2 d345622dex11.htm EX-1.1 Exhibit 1.1 3,250,000 SHARES TRANSMEDICS GROUP, INC. COMMON STOCK, NO PAR VALUE PER SHARE UNDERWRITING AGREEMENT August 4, 2022 August 4, 2022 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Cowen and Company, LLC as Representatives of the Several Underwriters listed in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 |
|
| August 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) TransMedics Group, Inc. |
|
| August 5, 2022 |
3,250,000 Shares TransMedics Group, Inc. Common stock Table of Contents Prospectus supplement (To prospectus dated August 3, 2022) 3,250,000 Shares TransMedics Group, Inc. |
|
| August 3, 2022 |
Statement of Eligibility of Trustee under the Indenture Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Emp |
|
| August 3, 2022 |
Subject to completion, dated August 3, 2022. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266493 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement is not an offer to sell these securities and it is not so |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| August 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) TransMedics Group, Inc. |
|
| August 3, 2022 |
Exhibit 4.4 TRANSMEDICS GROUP, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of [ ], [ ] TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.3. RULES OF CONSTRUCTION 5 ARTICLE 2. THE SECURITIES 6 2.1. ISSUABLE IN SERIES 6 2.2. ESTABLISHMENT OF TERMS OF SERIES |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2022 TransMedics Group, Inc. |
|
| August 1, 2022 |
Exhibit 99.1 TransMedics Reports Second Quarter 2022 Financial Results Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million Andover, Mass. ? August 1, 2022 - TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage |
|
| July 29, 2022 |
Exhibit 10.1 SENIOR SECURED CREDIT FACILITIES CREDIT AGREEMENT dated as of July 25, 2022, among TRANSMEDICS GROUP, INC., as the Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, and CANADIAN IMPERIAL BANK OF COMMERCE, as Administrative Agent Table of Contents Page SECTION I DEFINITIONS 1 1.1 Defined Terms 1 1.2 Dutch terms 30 1.3 Other Definitional Provisions 30 1.4 Rounding 31 1.5 Tim |
|
| July 29, 2022 |
Exhibit 10.2 GUARANTEE AND COLLATERAL AGREEMENT Dated as of July 25, 2022, made by TRANSMEDICS GROUP, INC., and the other Grantors referred to herein, in favor of CANADIAN IMPERIAL BANK OF COMMERCE, as Administrative Agent TABLE OF CONTENTS Page SECTION 1. DEFINED TERMS 1 1.1 Definitions 1 1.2 Other Definitional Provisions 5 SECTION 2. GUARANTEE 5 2.1 Guarantee 5 2.2 Right of Contribution 7 2.3 No |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2022 TransMedics Group, Inc. |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 3, 2022 |
TransMedics Reports First Quarter 2022 Financial Results Exhibit 99.1 TransMedics Reports First Quarter 2022 Financial Results Andover, Mass. - May 3, 2022 - TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2022. Recent Highlights ? Net revenue of $1 |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 TransMedics Group, Inc. |
|
| April 22, 2022 |
DEFA14A 1 d258683ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange ACT of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident |
|
| April 20, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange ACT of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| March 1, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) TransMedics Group, Inc. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Group, In |
|
| February 23, 2022 |
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results Andover, Mass. ? February 23, 2022 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2021. Rece |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 TransMedics Group, Inc. |
|
| February 14, 2022 |
TMDX / TransMedics Group Inc / CREDIT SUISSE AG/ - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* TransMedics Group, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2022 |
TMDX / TransMedics Group Inc / MACQUARIE GROUP LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Transmedics Group Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2022 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| November 9, 2021 |
TransMedics Reports Third Quarter 2021 Financial Results Exhibit 99.1 TransMedics Reports Third Quarter 2021 Financial Results Andover, Mass. ? November 9, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2021. Recent Highlights ? Net reve |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 TransMedics Group, Inc. |
|
| September 29, 2021 |
Exhibit 99.1 TransMedics, Inc Press Release | Sept 29, 2021 TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation Andover, Mass. ? September 29, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and |
|
| September 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2021 TransMedics Group, Inc. |
|
| September 7, 2021 |
Exhibit 99.1 TransMedics, Inc Press Release | Sept 7, 2021 TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplantation in the U.S. Andover, Mass. ? September 7, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, hea |
|
| September 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2021 TransMedics Group, Inc. |
|
| August 9, 2021 |
Exhibit 10.1 TRANSMEDICS GROUP, INC. INDUCEMENT PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those terms. 2. PURPOSE The Plan is intended to advance the interests of the Company by providing for the grant to Participants of Stock and Stock-based Awards as an inducement to secure and retain th |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 TransMedics Group, Inc. |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| August 5, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 TransMedics Group, Inc. |
|
| August 5, 2021 |
TransMedics Reports Second Quarter 2021 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2021 Financial Results Andover, Mass. ? August 5, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021. Recent Highlights ? Net revenue of |
|
| July 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2021 TransMedics Group, Inc. |
|
| July 15, 2021 |
Exhibit 99.1 TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System Panel votes unanimously in support of the OCS Liver System?s safety and effectiveness Andover, Mass. ? July 14, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver fa |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 4, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 TransMedics Group, Inc. |
|
| May 4, 2021 |
TransMedics Reports First Quarter 2021 Financial Results Exhibit 99.1 TransMedics Reports First Quarter 2021 Financial Results Andover, Mass. ? May 4, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021. Recent Highlights ? Net revenue of $7 |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 7, 2021 |
Exhibit 99.1 TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System Panel votes 12 to 5 that benefits of OCS Heart System outweigh risks Andover, Mass. ? April 6, 2021 ? TransMedics Group, Inc. (?TransMedics?) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced toda |
|
| April 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2021 TransMedics Group, Inc. |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2021 TransMedics Group, Inc. |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Gr |
|
| March 2, 2021 |
TransMedics Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2020 Financial Results Andover, Mass. – March 2, 2021 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter and year ended December 31, 2020. Recent Hi |
|
| March 2, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2021 TransMedics Group, Inc. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TransMedics Group, Inc. (Name of Issuer) Common Stock, No par value (Title of Class of Securities) 89377M109 (CUSIP Number) February 11, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 12, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* TransMedics Group, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 12, 2021 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio |
|
| February 10, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TransMedics Group, Inc. (Name of Issuer) Common Stock, No par value (Title of Class of Securities) 89377M109 (CUSIP Number) February 8, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| December 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2020 TransMedics Group, Inc. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| November 4, 2020 |
TransMedics Reports Third Quarter 2020 Financial Results TransMedics Reports Third Quarter 2020 Financial Results Andover, Mass. – November 4, 2020 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended September 30, 2020. Recent Highlights • Net revenue of $7.1 mi |
|
| November 4, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2020 TransMedics Group, Inc. |
|
| August 10, 2020 |
Exhibit 10.1 OMNIBUS AMENDMENT #2 TO LEASE 200 Minuteman and 30 Minuteman This OMNIBUS AMENDMENT #2 TO LEASE (this “Amendment”) is entered into and dated as of the 1st day of June 2020 (the “Omnibus Amendment #2 Effective Date”), by and between WHETSTONE 200 MINUTEMAN PARK, LLC, a Delaware limited liability company (“200 Minuteman Landlord”), and WHETSTONE 30 MINUTEMAN PARK, LLC, a Delaware limite |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| August 5, 2020 |
TransMedics Reports Second Quarter 2020 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2020 Financial Results Andover, Mass. – August 5, 2020 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights • OCS Heart FDA A |
|
| August 5, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2020 TransMedics Group, Inc. |
|
| June 8, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 5, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 2, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2020 TransMedics Group, Inc. |
|
| May 28, 2020 |
EX-1.1 Exhibit 1.1 5,000,000 SHARES TRANSMEDICS GROUP, INC. COMMON STOCK, NO PAR VALUE PER SHARE UNDERWRITING AGREEMENT May 26, 2020 May 26, 2020 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC as Representatives of the Several Underwriters listed in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, |
|
| May 28, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 27, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238052 Preliminary prospectus supplement (To prospectus dated May 21, 2020) 5,000,000 shares TransMedics Group, Inc. Common stock We are selling 5,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “TMDX”. On May 26, 2020, the last reported sale price of our common |
|
| May 26, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238052 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement is not an offer to sell these securities and it is |
|
| May 26, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2020 TransMedics Group, Inc. |
|
| May 26, 2020 |
EX-99.1 Exhibit 99.1 TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allograft Dysfunction (EAD) Compared to Control. Andover, Mass. – May 26, 2020 – TransMedics Group, In |
|
| May 19, 2020 |
CORRESP TRANSMEDICS GROUP, INC. 200 Minuteman Road Andover, Massachusetts 01810 May 19, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Paul Fischer; Mary Beth Breslin Re: TransMedics Group, Inc. Registration Statement on Form S-3 (File No. 333-238052) Request for Acceleration Ladies and |
|
| May 19, 2020 |
CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW. |
|
| May 6, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| May 6, 2020 |
TransMedics Reports First Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 TransMedics Reports First Quarter 2020 Financial Results Andover, Mass. – May 06, 2020 (GLOBE NEWSWIRE) – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 31, 2020. “We began 20 |
|
| May 6, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on May 6, 2020 Registration No. |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d925734d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2020 TransMedics Group, Inc. (Exact Name of Registrant as Specified in Charter) Massachusetts 001-38891 83-2181531 (State or Other Jurisdiction of Incorp |
|
| April 28, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2020 TransMedics Group, Inc. |
|
| April 24, 2020 |
EX-10.1 Exhibit 10.1 Promissory Note Date Loan Amount Interest Rate after Deferment Period Deferment Period April 20, 2020 $2,249,280.00 1.00% fixed per annum 6 months This Promissory Note (“Note”) sets forth and confirms the terms and conditions of a term loan to Transmedics Inc (whether one or more than one, “Borrower”) from Bank of America, NA, a national banking association having an address o |
|
| April 24, 2020 |
EX-10.2 Exhibit 10.2 SECOND Amendment TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of April 23, 2020 by and among TRANSMEDICS, INC., a Delaware corporation (the “Borrower”), TRANSMEDICS GROUP, INC., a Massachusetts corporation (“TransMedics Group”), and TRANSMEDICS B.V., a Dutch private limited liability company (besloten vennootschap |
|
| April 24, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2020 TransMedics Group, Inc. |
|
| April 14, 2020 |
DEF 14A 1 d852028ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 14, 2020 |
TMDX / TransMedics Group, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 13, 2020 |
EX-10.1 Exhibit 10.1 AMENDMENT TO EXECUTIVE RETENTION AGREEMENT This amendment (this “Amendment”) amends the terms of the Executive Retention Agreement, by and between TransMedics, Inc., a Delaware corporation (the “Company”), and Stephen Gordon (the “Executive”), dated as of March 23, 2015 (the “Retention Agreement”), as follows: 1. Amendment. Section 2 of the Retention Agreement is hereby amende |
|
| April 13, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2020 TransMedics Group, Inc. |
|
| April 13, 2020 |
EX-99.1 Exhibit 99.1 TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020 Andover, Mass. April 13, 2020 TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced actions it is taking in re |
|
| March 17, 2020 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of TransMedics Group, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF COMMON STOCK Th |
|
| March 17, 2020 |
Exhibit 3.1 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Restated Articles of Organization (General Laws Chapter 156D, Section 10.07; 950 CMR 113.35) (1) Exact name of corporation: TransMedics Group, Inc. (2) Registered office address: 84 State Street, Boston, MA 02109 (number, street, city or town, sta |
|
| March 17, 2020 |
FOR VALIDATION PURPOSES ONLY - [825310.EX1026] Exhibit 10.26 OMNIBUS AMENDMENT #1 TO LEASE 200 Minuteman and 30 Minuteman This OMNIBUS AMENDMENT #1 TO LEASE (this “Amendment”) is entered into and dated as of the 9th day of January, 2020 (the “Amendment Date”); however, is effective retroactively as of the 23rd day of December, 2019 (the “Effective Date”) by and between WHETSTONE 200 MINUTEMAN PARK |
|
| March 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Gr |
|
| March 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2020 TransMedics Group, Inc. |
|
| March 4, 2020 |
TransMedics Reports Fourth Quarter and Full Year 2019 Financial Results Exhibit 99.1 TransMedics Reports Fourth Quarter and Full Year 2019 Financial Results Andover, Mass. – March 2, 2020 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter and year ended December 28, 2019. Recent Hi |
|
| February 28, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2020 TransMedics Group, Inc. |
|
| February 28, 2020 |
EX-10.1 Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 27, 2020 by and among TRANSMEDICS, INC., a Delaware corporation (the “Borrower”), TRANSMEDICS GROUP, INC., a Massachusetts corporation (“TransMedics Group”), and TRANSMEDICS B.V., a Dutch private limited liability company (be |
|
| February 13, 2020 |
TMDX / TransMedics Group, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* TransMedics Group, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 13, 2020 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio |
|
| February 13, 2020 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio |
|
| February 13, 2020 |
TMDX / TransMedics Group, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* TransMedics Group, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 13, 2020 |
TMDX / TransMedics Group, Inc. / ABRAMS CAPITAL MANAGEMENT, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TransMedics Group, Inc. (Name of Issuer) Common Stock, No par value (Title of Class of Securities) 89377M109 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 13, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement is by and among Abrams Capital Partners II, L.P., Abrams Capital, LLC, Abrams Capital Management, LLC, Abrams Capital Management, L.P., Riva Capital Partners III, L.P., Riva Capital Management III, LLC and David Abrams (collectively, the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchan |
|
| February 7, 2020 |
TMDX / TransMedics Group, Inc. / United Therapeutics Corp - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 15, 2020 |
EX-10.1 Exhibit 10.1 OMNIBUS AMENDMENT #1 TO LEASE 200 Minuteman and 30 Minuteman This OMNIBUS AMENDMENT #1 TO LEASE (this “Amendment”) is entered into and dated as of the 9th day of January, 2020 (the “Amendment Date”); however, is effective retroactively as of the 23rd day of December, 2019 (the “Effective Date”) by and between WHETSTONE 200 MINUTEMAN PARK, LLC, a Delaware limited liability comp |
|
| January 15, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2020 TransMedics Group, Inc. |
|
| January 13, 2020 |
EX-99.1 Exhibit 99.1 DBD Donors Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our results of operations, commercial opportunity and the rate of adoption and benefits of the OCS. Each forward-looking statement is subject to |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2020 TransMedics Group, Inc. |
|
| November 8, 2019 |
TMDX / TransMedics Group, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| November 6, 2019 |
TransMedics Reports Third Quarter 2019 Financial Results Exhibit 99.1 TransMedics Reports Third Quarter 2019 Financial Results Andover, Mass. – November 6, 2019 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended September 28, 2019. Recent Highlights • Net reven |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2019 TransMedics Group, Inc. |
|
| August 8, 2019 |
TMDX / TransMedics Group, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| August 7, 2019 |
TransMedics Reports Second Quarter 2019 Financial Results Exhibit 99.1 TransMedics Reports Second Quarter 2019 Financial Results Andover, Mass. – August 7, 2019 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 29, 2019. Recent Highlights • Recorded net re |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2019 TransMedics Group, Inc. |
|
| June 12, 2019 |
TMDX / TransMedics Group, Inc. 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. |
|
| June 11, 2019 |
TransMedics Reports First Quarter 2019 Financial Results EX-99.1 Exhibit 99.1 TransMedics Reports First Quarter 2019 Financial Results Andover, Mass. – June 11, 2019 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 30, 2019. Recent Highlights • Recorded |
|
| June 11, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2019 TransMedics Group, Inc. |
|
| June 4, 2019 |
EX-99.1 Exhibit 99.1 TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage Andover, Mass. – June 3, 2019 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy f |
|
| June 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2019 TransMedics Group, Inc. |
|
| May 6, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2019 TransMedics Group, Inc. |
|
| May 6, 2019 |
EX-10.1 Exhibit 10.1 NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Ninth Amended and Restated Investor Rights Agreement (this “Agreement”) dated as of May 6, 2019 is entered into by and among TransMedics Group, Inc., a Massachusetts corporation (the “Company”), TransMedics, Inc., a Delaware corporation (“TransMedics”), the holders of the Company’s Common Stock listed on Exhibit A-1 (th |
|
| May 6, 2019 |
EX-10.3 Exhibit 10.3 SUPPLEMENT TO PLEDGE AND SECURITY AGREEMENT This SUPPLEMENT, dated as of May 6, 2019 (this “Supplement”), is to the Pledge and Security Agreement, dated as of June 22, 2018 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Security Agreement”), among the Grantors (such term, and other terms used in this Supplement, to have the meanin |
|
| May 6, 2019 |
EX-10.2 Exhibit 10.2 SUPPLEMENT TO GUARANTEE This SUPPLEMENT, dated as of May 6, 2019 (this “Supplement”), is to the Guarantee, dated as of June 22, 2018 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Guarantee”), by the Guarantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Guarantee) from t |
|
| May 6, 2019 |
TMDX / TransMedics Group, Inc. S-8 S-8 S-8 As filed with the Securities and Exchange Commission on May 6, 2019 Registration No. |
|
| May 2, 2019 |
5,690,000 shares TransMedics Group, Inc. COMMON STOCK 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No. |
|
| May 1, 2019 |
EX-3.3 Exhibit 3.3 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Restated Articles of Organization (General Laws Chapter 156D, Section 10.07; 950 CMR 113.35) (1) Exact name of corporation: TransMedics Group, Inc. (2) Registered office address: 84 State Street, Boston, MA 02109 (number, street, city or to |
|
| May 1, 2019 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 TRANSMEDICS GROUP, INC. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi |
|
| May 1, 2019 |
TMDX / TransMedics Group, Inc. S-1MEF S-1MEF S-1MEF As filed with the Securities and Exchange Commission on May 1, 2019 Registration No. |
|
| May 1, 2019 |
TMDX / TransMedics Group, Inc. S-1/A S-1/A - AMENDMENT NO. 3 S-1/A - Amendment No. 3 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2019. Registration No. 333-230736 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts (State or |
|
| April 30, 2019 |
Exhibit 3.3 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Restated Articles of Organization (General Laws Chapter 156D, Section 10.07; 950 CMR 113.35) (1) Exact name of corporation: TransMedics Group, Inc. (2) Registered office address: 84 State Street, Boston, MA 02109 (number, street, city or town, sta |
|
| April 30, 2019 |
As filed with the Securities and Exchange Commission on April 29, 2019. Table of Contents As filed with the Securities and Exchange Commission on April 29, 2019. |
|
| April 29, 2019 |
TMDX / TransMedics Group, Inc. CORRESP - - CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW. |
|
| April 29, 2019 |
TMDX / TransMedics Group, Inc. CORRESP - - CORRESP April 29, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 29, 2019 |
TMDX / TransMedics Group, Inc. CORRESP - - CORRESP 1 filename1.htm TRANSMEDICS GROUP, INC. 200 Minuteman Road Andover, Massachusetts 01810 April 29, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Thomas Jones Heather Percival Re: TransMedics Group, Inc. Registration Statement on Form S-1 (File No. 333-230736) Request for Acceleration Ladies and Gentlemen: |
|
| April 22, 2019 |
Exhibit 10.10 Name: [ ] Number of Shares of Stock subject to the Stock Option: [ ] Exercise Price Per Share: $[ ] Date of Grant: [ ] [Vesting Commencement Date: [ ] TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT This agreement (this ?Agreement?) evidences a stock option granted by the Company to the individual named above (the ?Participant?), pursuant to and sub |
|
| April 22, 2019 |
As filed with the Securities and Exchange Commission on April 22, 2019. Table of Contents As filed with the Securities and Exchange Commission on April 22, 2019. |
|
| April 22, 2019 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (?Agreement?), dated as of April 15, 2019, is among TransMedics, Inc., a Delaware corporation (the ?Company?), TransMedics Group, Inc., a Massachusetts corporation and a wholly-owned subsidiary of the Company (?Holdings?), and TMDX, Inc., a Delaware corporation and a wholly-owned subsid |
|
| April 22, 2019 |
Exhibit 10.12 TRANSMEDICS GROUP, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those terms. 2. PURPOSE The Plan is intended to enable Eligible Employees to use payroll deductions to purchase shares of Stock in offerings under the Plan, and thereby acquire an i |
|
| April 22, 2019 |
Form of Ninth Amended and Restated Investor Rights Agreement Exhibit 10.1 NINTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Ninth Amended and Restated Investor Rights Agreement (this ?Agreement?) dated as of [ ], 2019 is entered into by and among TransMedics Group, Inc., a Massachusetts corporation (the ?Company?), TransMedics, Inc., a Delaware corporation (?TransMedics?), the holders of the Company?s Common Stock listed on Exhibit A-1 (the ?Former |
|
| April 22, 2019 |
Exhibit 10.35 THIRD WAIVER This THIRD WAIVER (this ?Waiver?) is made and entered into as of March 29, 2019 by and among TRANSMEDICS, INC., a Delaware corporation (the ?Borrower?), TRANSMEDICS B.V., a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) (the ?Guarantor?), and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (the ?Lender? |
|
| April 22, 2019 |
Exhibit 10.9 TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those terms. 2. PURPOSE The Plan is intended to advance the interests of the Company by providing for the grant to Participants of Stock and Stock-based Awards. The purposes of the Plan are |
|
| April 22, 2019 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS of TRANSMEDICS GROUP, INC. ARTICLE I Meetings of Shareholders Section 1. Place. Meetings of the shareholders shall be held at the principal office of the corporation or at such other place as may be determined by the board of directors or an officer designated by the board of directors and identified in the notice to shareholders of such meeting. Section 2. |
|
| April 22, 2019 |
Exhibit 10.13 TRANSMEDICS GROUP, INC. 2019 CASH INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those terms. 2. PURPOSE The Plan is intended to advance the interests of the Company by providing for the grant of cash-based incentive Awards to executive officers and key employees of the |
|
| April 22, 2019 |
TMDX / TransMedics Group, Inc. CORRESP - - CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW. |
|
| April 22, 2019 |
Exhibit 3.3 The Commonwealth of Massachusetts William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Restated Articles of Organization (General Laws Chapter 156D, Section 10.07; 950 CMR 113.35) (1) Exact name of corporation: TransMedics Group, Inc. (2) Registered office address: 84 State Street, Boston, MA 02109 (number, street, city or town, sta |
|
| April 22, 2019 |
Exhibit 10.11 Name: [ ] Number of Shares of Stock subject to the Stock Option: [ ] Exercise Price Per Share: $[ ] Date of Grant: [ ] Vesting Commencement Date: [ ] TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT This agreement (this ?Agreement?) evidences a stock option granted by the Company to the individual named above (the ?Participant?), pursuant to and |
|
| April 16, 2019 |
TMDX / TransMedics Group, Inc. CORRESP - - CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW. |
